JP2006513236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006513236A5 JP2006513236A5 JP2004564917A JP2004564917A JP2006513236A5 JP 2006513236 A5 JP2006513236 A5 JP 2006513236A5 JP 2004564917 A JP2004564917 A JP 2004564917A JP 2004564917 A JP2004564917 A JP 2004564917A JP 2006513236 A5 JP2006513236 A5 JP 2006513236A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- microparticles
- less
- particles
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 239000011859 microparticle Substances 0.000 claims 22
- 239000002245 particle Substances 0.000 claims 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims 12
- 239000013543 active substance Substances 0.000 claims 10
- 239000010419 fine particle Substances 0.000 claims 8
- 229920006395 saturated elastomer Polymers 0.000 claims 8
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 6
- 238000012387 aerosolization Methods 0.000 claims 6
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 6
- 229960003942 amphotericin b Drugs 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 6
- 239000011159 matrix material Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 230000002685 pulmonary effect Effects 0.000 claims 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- YKIOPDIXYAUOFN-UHFFFAOYSA-N 2,3-di(icosanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-UHFFFAOYSA-N 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 claims 2
- 229940112141 dry powder inhaler Drugs 0.000 claims 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- 239000006199 nebulizer Substances 0.000 claims 2
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 claims 2
- 229940067626 phosphatidylinositols Drugs 0.000 claims 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 2
- 150000008106 phosphatidylserines Chemical class 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000003380 propellant Substances 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43721002P | 2002-12-31 | 2002-12-31 | |
| PCT/US2003/041703 WO2004060351A2 (en) | 2002-12-31 | 2003-12-31 | Pharmaceutical formulation with an insoluble active agent for pulmonary administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006513236A JP2006513236A (ja) | 2006-04-20 |
| JP2006513236A5 true JP2006513236A5 (https=) | 2007-01-25 |
Family
ID=32713146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004564917A Withdrawn JP2006513236A (ja) | 2002-12-31 | 2003-12-31 | 不溶性活性物質を伴う医薬製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040156792A1 (https=) |
| EP (1) | EP1589947B2 (https=) |
| JP (1) | JP2006513236A (https=) |
| KR (1) | KR20050095838A (https=) |
| CN (1) | CN1741789A (https=) |
| AU (1) | AU2003300137A1 (https=) |
| BR (1) | BR0317810A (https=) |
| CA (1) | CA2511523C (https=) |
| EA (1) | EA200501001A1 (https=) |
| ES (1) | ES2589578T5 (https=) |
| HU (1) | HUP0500846A3 (https=) |
| MX (1) | MXPA05007158A (https=) |
| NO (1) | NO20053076L (https=) |
| PL (1) | PL378270A1 (https=) |
| PT (1) | PT1589947T (https=) |
| TR (1) | TR200502522T2 (https=) |
| WO (1) | WO2004060351A2 (https=) |
| ZA (1) | ZA200505155B (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| PT1280520E (pt) | 2000-05-10 | 2014-12-16 | Novartis Ag | Pós à base de fosfolípidos para administração de fármacos |
| PT1458360E (pt) | 2001-12-19 | 2011-07-13 | Novartis Ag | Derivados de indole como agonistas do recetor s1p1 |
| JP2006513235A (ja) * | 2002-12-31 | 2006-04-20 | ネクター セラピューティクス | 真菌感染症療法のためのエアゾール化可能な医薬製剤 |
| KR20060015316A (ko) | 2003-05-28 | 2006-02-16 | 넥타르 테라퓨틱스 | 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법 |
| US8513204B2 (en) * | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
| WO2006026502A1 (en) * | 2004-08-27 | 2006-03-09 | The Dow Chemical Company | Enhanced delivery of drug compositions to treat life threatening infections |
| CA2623256A1 (en) * | 2005-09-29 | 2007-04-12 | Nektar Therapeutics | Receptacles and kits, such as for dry powder packaging |
| ITMI20051999A1 (it) * | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| US20120128728A1 (en) * | 2005-12-28 | 2012-05-24 | Novartis Pharma Ag | Compositions Comprising Amphotericin B |
| IN2015DN00888A (https=) * | 2006-02-22 | 2015-07-10 | Mannkind Corp | |
| DE102006053375A1 (de) * | 2006-11-10 | 2008-05-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Mischung von Pulvern |
| SI2170279T1 (en) * | 2007-07-31 | 2018-04-30 | Otsuka Pharmaceutical Co., Ltd. | Methods for producing aripiprazole suspension and freeze-dried formulation |
| EP2050437A1 (en) * | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
| PL220269B1 (pl) | 2008-04-21 | 2015-09-30 | Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna | Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego |
| MX2010012452A (es) | 2008-05-15 | 2011-03-15 | Novartis Ag Star | Suministro pulmonar de una fluoro-quinolona. |
| EP3552602B1 (en) | 2009-03-18 | 2025-03-05 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| EP2411137B1 (en) | 2009-03-27 | 2016-09-07 | Bend Research, Inc. | Spray-drying process |
| GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| TR200904500A2 (tr) | 2009-06-10 | 2009-10-21 | Öner Levent | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. |
| EP2611529B1 (en) | 2010-09-03 | 2019-01-23 | Bend Research, Inc. | Spray-drying method |
| WO2012031133A2 (en) | 2010-09-03 | 2012-03-08 | Bench Research, Inc. | Spray-drying apparatus and methods of using the same |
| WO2012040502A1 (en) | 2010-09-24 | 2012-03-29 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
| AU2011320159B2 (en) | 2010-10-29 | 2016-12-22 | Western University Of Health Sciences | Ternary mixture formulations |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| CN106061487A (zh) * | 2014-02-03 | 2016-10-26 | 里兰斯坦福初级大学理事会 | 用于微粒递送锌原卟啉的制剂 |
| WO2016067132A1 (en) | 2014-10-31 | 2016-05-06 | Bend Research Inc. | Process for forming active domains dispersed in a matrix |
| CN104587457B (zh) * | 2015-01-13 | 2017-03-22 | 广东海大畜牧兽医研究院有限公司 | 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法 |
| CA3008996A1 (en) * | 2015-12-24 | 2017-06-29 | Philip Morris Products S.A. | Nicotine particle capsule |
| CN109069495A (zh) | 2016-02-01 | 2018-12-21 | 英凯达治疗公司 | 电子监测联合吸入药理学疗法管理包括心房颤动在内的心律失常 |
| AU2018266199A1 (en) | 2017-05-10 | 2019-11-07 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| IL269275B2 (en) * | 2017-06-28 | 2023-04-01 | Philip Morris Products Sa | Container with particles for use with an inhaler |
| US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
| GB201817860D0 (en) | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolised formulation |
| GB201817863D0 (en) | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
| GB201817865D0 (en) * | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
| AU2020323594B2 (en) | 2019-08-01 | 2022-02-03 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| US11007185B2 (en) | 2019-08-01 | 2021-05-18 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
| IL315719A (en) | 2022-03-21 | 2024-11-01 | Univ Illinois | Prosthetic assemblies of ion channels containing lipid-coated amphotericin B crystals |
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US437210A (en) | 1890-09-30 | Electric street-car | ||
| SE408265B (sv) * | 1975-12-12 | 1979-06-05 | Draco Ab | Anordning for koldioxiddriven endosaerosol, avsedd for inhalering |
| US4247066A (en) * | 1978-02-21 | 1981-01-27 | General Dynamics Corporation | Airfoil variable cambering device and method |
| IT1116047B (it) * | 1979-04-27 | 1986-02-10 | Sigma Tau Ind Farmaceuti | Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma |
| DE3634952A1 (de) * | 1986-10-14 | 1988-04-21 | Bayer Ag | Imidazo-pyrrolo-pyridin-derivate |
| US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| DE69230613T2 (de) * | 1991-07-02 | 2000-12-28 | Inhale Inc | Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform |
| US5785049A (en) * | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| JP3388896B2 (ja) * | 1994-08-08 | 2003-03-24 | 株式会社日立ユニシアオートモティブ | 吸入式投薬器 |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| ATE287703T1 (de) * | 1995-04-14 | 2005-02-15 | Nektar Therapeutics | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit |
| US6503480B1 (en) * | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| AU5719798A (en) * | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
| AU756693B2 (en) * | 1997-09-29 | 2003-01-23 | Novartis Ag | Stabilized bioactive preparations and methods of use |
| US20020017295A1 (en) * | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6257233B1 (en) * | 1998-06-04 | 2001-07-10 | Inhale Therapeutic Systems | Dry powder dispersing apparatus and methods for their use |
| WO2000001365A1 (en) † | 1998-06-30 | 2000-01-13 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) | Prolonged release ophthalmic compositions containing a fluoroquinolone |
| US20010036481A1 (en) * | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| PT1280520E (pt) † | 2000-05-10 | 2014-12-16 | Novartis Ag | Pós à base de fosfolípidos para administração de fármacos |
| US6357490B1 (en) * | 2000-08-22 | 2002-03-19 | Advanced Inhalation Research, Inc. | System, method and apparatus for filling containers |
| KR100743404B1 (ko) * | 2000-12-21 | 2007-07-30 | 넥타르 테라퓨틱스 | 폴리엔 항균제의 폐 전달 |
-
2003
- 2003-12-31 US US10/750,934 patent/US20040156792A1/en not_active Abandoned
- 2003-12-31 JP JP2004564917A patent/JP2006513236A/ja not_active Withdrawn
- 2003-12-31 ES ES03800395T patent/ES2589578T5/es not_active Expired - Lifetime
- 2003-12-31 WO PCT/US2003/041703 patent/WO2004060351A2/en not_active Ceased
- 2003-12-31 EP EP03800395.0A patent/EP1589947B2/en not_active Expired - Lifetime
- 2003-12-31 CA CA2511523A patent/CA2511523C/en not_active Expired - Fee Related
- 2003-12-31 TR TR2005/02522T patent/TR200502522T2/xx unknown
- 2003-12-31 KR KR1020057012444A patent/KR20050095838A/ko not_active Withdrawn
- 2003-12-31 PT PT38003950T patent/PT1589947T/pt unknown
- 2003-12-31 MX MXPA05007158A patent/MXPA05007158A/es unknown
- 2003-12-31 HU HU0500846A patent/HUP0500846A3/hu unknown
- 2003-12-31 PL PL378270A patent/PL378270A1/pl unknown
- 2003-12-31 EA EA200501001A patent/EA200501001A1/ru unknown
- 2003-12-31 CN CNA2003801091328A patent/CN1741789A/zh active Pending
- 2003-12-31 BR BR0317810-2A patent/BR0317810A/pt not_active IP Right Cessation
- 2003-12-31 AU AU2003300137A patent/AU2003300137A1/en not_active Abandoned
-
2005
- 2005-06-23 NO NO20053076A patent/NO20053076L/no not_active Application Discontinuation
- 2005-06-24 ZA ZA200505155A patent/ZA200505155B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006513236A5 (https=) | ||
| AU2002352836B2 (en) | Improved particulate compositions for pulmonary delivery | |
| AU2002242253B2 (en) | Modulation of release from dry powder formulations | |
| AU2002258865B2 (en) | Large, porous particles produced controlling humidity during a spray drying process | |
| US6586008B1 (en) | Use of simple amino acids to form porous particles during spray drying | |
| US7807200B2 (en) | Formulations for spray-drying large porous particles | |
| US8404276B2 (en) | Pulmonary delivery for levodopa | |
| US20060147520A1 (en) | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation | |
| AU768299B2 (en) | Formulation for spray-drying large porous particles | |
| CA2382821A1 (en) | Modulation of release from dry powder formulations | |
| AU2003230689B2 (en) | Inhalable sustained therapeutic formulations | |
| AU2002242253A1 (en) | Modulation of release from dry powder formulations | |
| AU2002258865A1 (en) | Large, porous particles produced controlling humidity during a spray drying process | |
| CA2585859C (en) | Particles for treatment of pulmonary infection | |
| AU2006220411B2 (en) | Inhalable Sustained Therapeutic Formulations | |
| KR102666667B1 (ko) | 흡입용 건조 분말 제형 |